KeyBank National Association
IONS icon

KeyBank National Association’s Ionis Pharmaceuticals IONS Stock Holding History

KeyBank National Association’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,500
Closed -$337K – 1073
2021
Q1 		$337K Hold
7,500
– – ﹤0.01% 896
2020
Q4 		$424K Hold
7,500
– – ﹤0.01% 811
2020
Q3 		$356K Sell
7,500
-117
-2% -$6.5K ﹤0.01% 794
2020
Q2 		$449K Hold
7,617
– – ﹤0.01% 707
2020
Q1 		$360K Sell
7,617
-6,122
-45% -$341K ﹤0.01% 718
2019
Q4 		$830K Buy
13,739
+6,622
+93% +$395K ﹤0.01% 590
2019
Q3 		$426K Sell
7,117
-2,919
-29% -$190K ﹤0.01% 754
2019
Q2 		$645K Sell
10,036
-6,957
-41% -$492K ﹤0.01% 673
2019
Q1 		$1.38M Sell
16,993
-4,613
-21% -$298K 0.01% 431
2018
Q4 		$1.17M Buy
21,606
+250
+1% +$12.8K 0.01% 440
2018
Q3 		$1.1M Sell
21,356
-1,982
-8% -$93.1K 0.01% 519
2018
Q2 		$972K Buy
23,338
+764
+3% +$33.9K 0.01% 551
2018
Q1 		$995K Buy
22,574
+9,840
+77% +$500K 0.01% 532
2017
Q4 		$641K Buy
12,734
+4,254
+50% +$233K ﹤0.01% 686
2017
Q3 		$430K Hold
8,480
– – ﹤0.01% 825
2017
Q2 		$431K Sell
8,480
-7,523
-47% -$350K ﹤0.01% 862
2017
Q1 		$643K Sell
16,003
-5,001
-24% -$225K ﹤0.01% 747
2016
Q4 		$1M Buy
21,004
+6,478
+45% +$256K 0.01% 590
2016
Q3 		$532K Sell
14,526
-4,387
-23% -$137K ﹤0.01% 809
2016
Q2 		$440K Buy
18,913
+11,463
+154% +$370K ﹤0.01% 821
2016
Q1 		$302K Sell
7,450
-3,014
-29% -$122K ﹤0.01% 933
2015
Q4 		$648K Buy
10,464
+5,106
+95% +$276K ﹤0.01% 700
2015
Q3 		$217K Sell
5,358
-6,635
-55% -$343K ﹤0.01% 1048
2015
Q2 		$690K Sell
11,993
-3,098
-21% -$197K ﹤0.01% 715
2015
Q1 		$961K Buy
15,091
+5,757
+62% +$391K 0.01% 651
2014
Q4 		$576K Sell
9,334
-11,143
-54% -$550K ﹤0.01% 805
2014
Q3 		$795K Sell
20,477
-8,966
-30% -$318K 0.01% 693
2014
Q2 		$1.01M Sell
29,443
-845
-3% -$26.6K 0.01% 655
2014
Q1 		$1.31M Buy
+30,288
New +$1.47M 0.01% 551

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

KeyBank National Association's IONS Position: Q2 2021 in Review

KeyBank National Association sold out of Ionis Pharmaceuticals (IONS) in Q2 2021, closing a stake of 7,500 shares — an estimated $337K sold.

KeyBank National Association first reported a position in IONS in Q1 2014 and held it in 29 quarters. The position peaked at $1.38M in Q1 2019. 337 funds tracked by Wall St. Rank hold IONS as of Q2 2021.

  • KeyBank National Association reported no remaining Ionis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • KeyBank National Association sold 7,500 Ionis Pharmaceuticals shares in Q2 2021, an estimated $337K.
  • KeyBank National Association first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 29 quarters.
  • KeyBank National Association's Ionis Pharmaceuticals position peaked at $1.38M in Q1 2019.
  • 337 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2021.

Based on KeyBank National Association's 13F filing for Q2 2021, filed 12 Aug 2021.